Abstract: An oral presentation is a key stressor in a work environment. High levels of stress might abruptly decrease the quality and quantity of information that needs to be delivered to the audience ...

Clay Halton was a Business Editor at Investopedia and has been working in the finance publishing field for more than five years. He also writes and edits personal finance content, with a focus on ...

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well ...

IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...

– In addition to robust liver-centric effects, HU6 resulted in fat-selective weight loss with preservation of skeletal muscle mass; potential to address the metabolic dysfunction underlying MASH – – ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced ...

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial WALTHAM, Mass.- ...

For presentations scheduled prior to 1:00 PM, please go to the SHED Atrium between 8:00 and 8:30 AM and load your final presentation. For presentations scheduled after 1:00 PM, please go to the SHED ...

Please provide your email address to receive an email when new articles are posted on . Mid- to late-career medical oncologists from NCI-designated cancer centers delivered a high percentage of oral ...

All 67 squamous NSCLC patients were EGFR wild type. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the two groups of ...

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...